A class of prescription medications known as GLP-1 drugs is upending how employers pay for their workers' health coverage. STAT's Health Care Inc. newsletter, written by reporter Bob Herman, describes these drugs as acting "almost single-handedly" to force that rethinking. That is a pointed claim.
The phrase places one drug category at the center of something employers rarely overhaul: the basic structure of how they fund employee health benefits. Cost pressures in employer health care typically arrive from many directions at once. Attributing the shift primarily to one drug class is the story's core argument.
Health Care Inc. is a weekly email newsletter from STAT, a medical news outlet. Bob Herman covers the business side of health care. His current edition frames the employer reckoning around GLP-1 drugs as happening now, not as a coming pressure employers have time to weigh.